Table 2. Gene Set Enrichment Analysis on gene expression profiles from HMEC-1 following “acute” and “chronic” exposure to bleomycin and cisplatin, using pathway definitions from KEGG.
| BLEOMYCIN - ACUTE | CISPLATIN - ACUTE | CISPLATIN - CHRONIC | ||||
|---|---|---|---|---|---|---|
| FDR | P-value | FDR | P-value | FDR | P-value | |
| Cellular Processes; Cell Communication | ||||||
| Adherens junction | ↓ 0.07 | 0.003 | ||||
| Focal adhesion | ↓ 0.04 | <0.0001 | ||||
| Cellular Processes; Cell Growth and Death | ||||||
| p53 signalling pathway | ↑ 0.001 | <0.0001 | ↑ 0.02 | <0.0001 | ↓ 0.1 | <0.0001 |
| Environmental Information Processing; Signal Transduction | ||||||
| TGF-beta signalling pathway | ↓ 0.05 | <0.0001 | ||||
| Genetic Information Processing; Folding, Sorting and Degradation | ||||||
| Ubiquitin mediated proteolysis | ↓ 0.04 | 0.001 | ||||
| Human Diseases | ||||||
| Endometrial cancer | ↓ 0.04 | <0.0001 | ||||
| Cholera infection | ↑ 0.10 | 0.005 | ||||
| Type I Diabetes Mellitus | ↑ 0.07 | <0.0001 | ↑ 0.05 | <0.0001 | ↓ 0.01 | <0.0001 |
| Neurodegerative disease | ↓ 0.09 | 0.008 | ||||
| Prion diseases | ↓ 0.08 | 0.01 | ||||
| Metabolism; Carbohydrate Metabolism | ||||||
| Butanoate metabolism | ↑ 0.02 | <0.0001 | ||||
| Glyoxylate and dicarboxylate metabolism | ↓ 0.09 | 0.02 | ||||
| Reductive carboxylate cycle | ↓ 0.04 | 0.002 | ||||
| Glycosylphosphatidylinositol(GPI)-anchor biosynthesis | ↑ 0.03 | 0.002 | ||||
| N-Glycan biosynthesis | ↓ 0.08 | <0.0001 | ||||
| Linoleic acid metabolism | ↑ 0.08 | 0.005 | ↑ 0.09 | 0.01 | ||
| Polyunsatyrated fatty acid biosynthesis | ↓ 0.04 | 0.002 | ||||
| Organismal Systems; Immune System | ||||||
| Antigen processing and presentation | ↓ 0.0 | <0.0001 | ||||
| Toll-like receptor signalling pathway | ↓ 0.08 | <0.0001 | ||||
No pathways were enriched according to these criteria after “chronic” exposure to bleomycin.